Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R J Hohl

Showing results (21-30 of 44) with videos related to

Pageof 5
Sort By:
Investigational New Drugs|January 1, 1996
Phase II trial of edatrexate in patients with metastatic colorectal cancerG H Clamon, C E Riggs, R Dreicer, et al.
Bone Marrow Transplantation|July 1, 1995
Engraftment syndrome in autologous bone marrow and peripheral stem cell transplantationC K Lee, R D Gingrich, R J Hohl, et al.
Bone Marrow Transplantation|September 1, 1996
Fatal cyclophosphamide cardiomyopathy: its clinical course and treatmentC K Lee, G S Harman, R J Hohl, et al.
Bioorganic & Medicinal Chemistry|November 1, 2000
Synthesis of phosphonate derivatives of uridine, cytidine, and cytosine arabinosideK Y Jung, R J Hohl, A J Wiemer, et al.
Blood|December 15, 1996
Lovastatin inhibits T-cell antigen receptor signaling independent of its effects on rasF Goldman, R J Hohl, J Crabtree, et al.
Lipids|February 21, 1998
Stereochemistry-dependent inhibition of RAS farnesylation by farnesyl phosphonic acidsR J Hohl, K A Lewis, D M Cermak, et al.
Bioorganic & Medicinal Chemistry|July 29, 1998
Phosphonate and bisphosphonate analogues of farnesyl pyrophosphate as potential inhibitors of farnesyl protein transferaseS A Holstein, D M Cermak, D F Wiemer, et al.
Clinical Pharmacology and Therapeutics|June 22, 2011
Clinical pharmacology as a foundation for translational scienceS A Waldman, R J Hohl, G L Kearns, et al.
American Journal of Hematology|November 3, 1998
Low pulse oximeter-measured hemoglobin oxygen saturations with hemoglobin CheverlyR J Hohl, A R Sherburne, J E Feeley, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 17, 2001
Changes in erythropoietin pharmacokinetics following busulfan-induced bone marrow ablation in sheep: evidence for bone marrow as a major erythropoietin elimination pathwayS Chapel, P Veng-Pedersen, R J Hohl, et al.
Pageof 5

Showing results (21-30 of 44) with videos related to

Sort By:
Pageof 5
Investigational New Drugs|January 1, 1996
Phase II trial of edatrexate in patients with metastatic colorectal cancerG H Clamon, C E Riggs, R Dreicer, et al.
Bone Marrow Transplantation|July 1, 1995
Engraftment syndrome in autologous bone marrow and peripheral stem cell transplantationC K Lee, R D Gingrich, R J Hohl, et al.
Bone Marrow Transplantation|September 1, 1996
Fatal cyclophosphamide cardiomyopathy: its clinical course and treatmentC K Lee, G S Harman, R J Hohl, et al.
Bioorganic & Medicinal Chemistry|November 1, 2000
Synthesis of phosphonate derivatives of uridine, cytidine, and cytosine arabinosideK Y Jung, R J Hohl, A J Wiemer, et al.
Blood|December 15, 1996
Lovastatin inhibits T-cell antigen receptor signaling independent of its effects on rasF Goldman, R J Hohl, J Crabtree, et al.
Lipids|February 21, 1998
Stereochemistry-dependent inhibition of RAS farnesylation by farnesyl phosphonic acidsR J Hohl, K A Lewis, D M Cermak, et al.
Bioorganic & Medicinal Chemistry|July 29, 1998
Phosphonate and bisphosphonate analogues of farnesyl pyrophosphate as potential inhibitors of farnesyl protein transferaseS A Holstein, D M Cermak, D F Wiemer, et al.
Clinical Pharmacology and Therapeutics|June 22, 2011
Clinical pharmacology as a foundation for translational scienceS A Waldman, R J Hohl, G L Kearns, et al.
American Journal of Hematology|November 3, 1998
Low pulse oximeter-measured hemoglobin oxygen saturations with hemoglobin CheverlyR J Hohl, A R Sherburne, J E Feeley, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 17, 2001
Changes in erythropoietin pharmacokinetics following busulfan-induced bone marrow ablation in sheep: evidence for bone marrow as a major erythropoietin elimination pathwayS Chapel, P Veng-Pedersen, R J Hohl, et al.
Pageof 5